PharmaCyte Biotech (PMCB) Amortizatization of Intangibles (2010 - 2012)
PharmaCyte Biotech (PMCB) posted quarterly Amortizatization of Intangibles of -$5695.0 for Q3 2012, down 111.0% year-over-year from $51753.6 in Q3 2011, and down 110.85% quarter-over-quarter from -$2701.0 in Q2 2012.
PharmaCyte Biotech (PMCB) Amortizatization of Intangibles (2010 - 2012) Analysis & Trends
PharmaCyte Biotech (PMCB) has reported Amortizatization of Intangibles for 3 consecutive years, with -$5695.0 the latest figure, recorded in Q3 2012.
- In Q3 2012, Amortizatization of Intangibles fell 111.0% year-over-year to -$5695.0; the TTM figure through Apr 2013 stood at -$5695.0 (up 47.26% YoY), while the FY2013 annual figure was -$5695.0, up 47.26% from the prior year.
- Amortizatization of Intangibles fell to -$5695.0 in Q3 2012 per PMCB's latest filing, from -$2701.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at -$2699.0 in Q3 2010 and bottomed at -$5695.0 in Q3 2012.
- Historically, Amortizatization of Intangibles has averaged -$3032.3 across 3 years, with a median of -$2699.0 in 2010.
- Annual changes were most pronounced in 2011 — Amortizatization of Intangibles changed 0.0% — and 2012, when it tumbled 111.0%.
- PharmaCyte Biotech's Amortizatization of Intangibles stood at -$2699.0 in 2010, then changed by 0.0% to -$2699.0 in 2011, then plunged by 111.0% to -$5695.0 in 2012.
- Business Quant data shows PMCB's Amortizatization of Intangibles at -$5695.0 in Q3 2012, -$2701.0 in Q2 2012, and -$2699.0 in Q1 2012.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | PharmaCyte Biotech | 4.38 Mn | 4.38 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2012 | -5,695.00 |
| Jul 31, 2012 | -5,695.00 |
| Apr 30, 2012 | -2,701.00 |
| Apr 30, 2012 | -2,701.00 |
| Jan 31, 2012 | -2,699.00 |
| Jan 31, 2012 | -2,699.00 |
| Oct 31, 2011 | -2,699.00 |
| Oct 31, 2011 | -2,699.00 |
| Jul 31, 2011 | -2,699.00 |
| Jul 31, 2011 | -2,699.00 |
| Apr 30, 2011 | -2,701.00 |
| Apr 30, 2011 | -2,701.00 |
| Jan 31, 2011 | -2,699.00 |
| Jan 31, 2011 | -2,699.00 |
| Oct 31, 2010 | -2,699.00 |
| Oct 31, 2010 | -2,699.00 |
| Jul 31, 2010 | -2,699.00 |
| Jul 31, 2010 | -2,699.00 |